Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapyProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationOptimizing combination therapies with existing and future CML drugsAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsAurora A is essential for early embryonic development and tumor suppressionReal-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Aurora kinase inhibitors--rising stars in cancer therapeutics?A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Targeting the cancer kinome through polypharmacology.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Danusertib, an aurora kinase inhibitor.Update on aurora kinase inhibitors in gynecologic malignancies.Update on Aurora Kinase Targeted Therapeutics in Oncology.The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabineThe novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibNovel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generatAurora kinase inhibitors as anticancer molecules.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)The potential role of Aurora kinase inhibitors in haematological malignancies.Abl tyrosine kinases in T-cell signalingAbl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia.Overcoming resistance in chronic myelogenous leukemia.Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.New drugs for chronic myelogenous leukemia.
P2860
Q21245716-4A521C22-EA0B-492B-AF95-08EAFFBC444FQ24607114-D53452E8-CAB2-4220-92E1-EBDFAE4A1A7BQ27667290-D210EFDA-D471-419A-BAE7-3F37DF35B368Q27667482-12CDC45B-4177-41A6-9884-206C5A2020DEQ27698001-A5868527-739C-4DAC-8730-3A6A7D323DF0Q28475255-0BF9AAB5-840F-43A0-830A-F54C30231E8FQ28477903-97FCCA44-4A96-49D7-9CDF-29AC3B816878Q28484913-E254F51A-78B1-4E99-99C8-8917F9664107Q28545195-C9C9E02A-DE55-4966-8811-2F5088B5CD4BQ28590685-65704204-F5B7-4E2F-AED9-4B3F1D8775D6Q30512706-FEA1BB85-BE10-4B52-9A11-0B4E57B7F419Q33392977-E7702035-83F4-4277-BE54-ACC2F61E692BQ33647643-E332F734-C481-4C91-8CF3-E77F19C66659Q33676809-172ED321-14DB-4169-87FB-CF6A90FB5AC5Q33878636-0B800F19-C613-4AD4-8652-2C03A2B777A7Q33893019-22324CB3-4FAE-4FE7-902A-E7A693AAE70DQ33903030-FBB44DB8-5C35-43F2-AB89-EDFD01B7D85BQ34126899-0D2A7F54-D0F5-4550-BCB0-3FB36DFAAA82Q34576017-5E31CFAA-8F73-4C18-AFC5-BE1E1651482FQ34941504-7C9775C5-A203-416D-8534-9ABB00C8DC77Q34979606-A04ACEB2-3F7C-4C06-A623-0BE3FF9D8381Q35377275-5770665E-5582-4421-9CD2-C21264D7010BQ35579430-539737DD-61E6-43D2-8F37-6E270D6D1C5DQ35773205-9F418B85-A1E6-419D-9735-E218317E6454Q35800825-96B72688-8F9F-44C7-B6B5-D9BE9CE6F200Q35850203-8238CA40-6148-401F-A5A2-39F956628D0CQ35946822-DADFA1A8-7B96-4837-A435-FE801B823C82Q36373227-710C2D20-42F2-4302-9ED2-77161A3457C3Q37167047-8662EA57-B985-4A2B-9D48-038ADF8417CCQ37182419-2224F525-99BE-48F1-BF73-552E862F6FC5Q37256808-BE4C6FE5-1788-47BA-BF4C-5052FAEB5BDBQ37328115-27A22756-0936-4B3E-BFF9-1E23D722EF98Q37385584-F824ED5C-CF16-4B3A-AA27-937CCF9E2550Q37613047-D89AD3B0-F129-48A4-9D9C-E564DE439A62Q37626054-7E41033B-1F06-48BB-8564-493B788B8ABEQ37657488-180F2667-9A40-4B4A-B654-970A413CA76FQ37690579-129E2056-BD68-441F-8CB1-256A85F70F6DQ37763106-88C8A0C5-2089-4225-A646-13BD642DDC8CQ37810115-6360055D-BE76-48F6-9572-E0A8745E94B6Q37843769-3BEC2834-1A9B-427A-B992-CDE516BB7281
P2860
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Simultaneous targeting of Auro ...... ABL mutations including T315I.
@en
type
label
Simultaneous targeting of Auro ...... ABL mutations including T315I.
@en
prefLabel
Simultaneous targeting of Auro ...... ABL mutations including T315I.
@en
P2093
P1433
P1476
Simultaneous targeting of Auro ...... ABL mutations including T315I.
@en
P2093
Alessio Graziano
Artur Gontarewicz
Carsten Bokemeyer
Daniel Benten
Enrico Pesenti
Gunhild Keller
Jürgen Moll
Riccardo Colombo
Stefan Balabanov
Tim H Brümmendorf
P304
P356
10.1182/BLOOD-2007-09-113175
P407
P577
2008-02-11T00:00:00Z